Home » Posts tagged with » Massachusetts
Merck acquires ArQule for $2.7bn to further diversify oncology pipeline

Merck acquires ArQule for $2.7bn to further diversify oncology pipeline

Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the deal in December 2019 in a move to further diversify its oncology pipeline with the Massachusetts-based ArQule focused on developing kinase […]

Roche signs $2.85bn deal with Sarepta for SRP-9001 DND gene therapy

Roche has signed a licensing deal worth up to $2.85 billion with Sarepta Therapeutics for the exclusive ex-US commercial rights to the latter’s SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), an investigational gene therapy for Duchenne muscular dystrophy (DMD). As per the agreement terms, Sarepta Therapeutics will get an upfront payment made up of $750 million in cash and $400 […]

Continue reading …
Glaukos closes Avedro acquisition to expand corneal health franchise

Glaukos acquisition of Avedro : Glaukos Corporation, a California-based ophthalmic medical technology and pharmaceutical company, has completed its previously announced acquisition of Avedro. Based in Waltham, Massachusetts, Avedro is a hybrid ophthalmic pharmaceutical and medical technology company, which is focused on treating corneal disease and disorders and enhancing vision to decrease dependency on eyeglasses or […]

Continue reading …
CD&R to acquire Cynosure medical aesthetics business from Hologic for $205m

Clayton, Dubilier & Rice (CD&R), a New York-based private equity firm, has signed an all-cash deal worth $205 million to acquire Cynosure, a medical aesthetics technology company, from US medical device company Hologic. Based in Massachusetts, Cynosure provides medical aesthetic treatment systems for plastic surgeons, dermatologists, medical spas and other healthcare practitioners. Cynosure’s product portfolio […]

Continue reading …
Roche to acquire US biotech company Promedior for $1.4bn

Roche acquisition of Promedior : Swiss drugmaker Roche has agreed to acquire Massachusetts-based biotech company Promedior in a deal worth up to $1.39 billion, as per the latest pharma acquisition news. The acquisition will give full rights for the Swiss pharma giant to Promedior’s portfolio of molecules targeting serious fibrotic diseases, including PRM-151, which holds […]

Continue reading …
WIRB-Copernicus acquires clinical trial consultant Waife & Associates

WIRB-Copernicus Group (WCG), a clinical services organization, said that its clinical services division has acquired Waife & Associates (W&A), a provider of management consulting services for biopharma clinical research clients. Financial terms of the acquisition were not disclosed by the parties. Waife & Associates is engaged in making clinical development more efficient and productive by […]

Continue reading …
MicroMedicine to introduce new white blood cell isolation technology at SITC annual conference

MicroMedicine, a US life sciences technology company, will launch Sorterra Cell Isolation System, a white blood cell isolation technology, at the 34th Society for Immunotherapy of Cancer (SITC) annual conference to be held from November 6-10 in National Harbour, Maryland. Sorterra Cell Isolation System will separate white blood cells from human peripheral blood preserving sample […]

Continue reading …
ProTom Radiance 330 proton therapy system bags FDA 510(k) Clearance

ProTom International has been given 510(k) clearance from the US Food and Drug Administration (FDA) for its Radiance 330 proton therapy system installed at the Massachusetts General Hospital (MGH) in Boston. According to the proton therapy technology manufacturer, the installed Radiance 330 proton therapy system is a compact, single-room system, which features an advanced pencil […]

Continue reading …
Siemens Healthineers to acquire Corindus Vascular Robotics for $1.1bn

Siemens Healthineers, through its subsidiary Siemens Medical Solutions, has agreed to acquire US-based Corindus Vascular Robotics, a developer of precision vascular robotics, for around $1.1 billion. Headquartered in Waltham, Massachusetts, Corindus Vascular Robotics is engaged in developing robotic solutions for transforming the treatment of emergent conditions. The company’s CorPath platform is said to be the […]

Continue reading …
Vertex to acquire Semma Therapeutics to advance stem cell-based treatments for type 1 diabetes

Vertex acquisition of Semma Therapeutics : US biotechnology company Vertex Pharmaceuticals has agreed to acquire privately-held biotechnology company Semma Therapeutics for $950 million in cash, as per the latest pharma acquisition news. Both the pharma companies are based in Massachusetts. Post-acquisition, Vertex Pharmaceuticals will advance curative cell-based treatments of Semma Therapeutics for type 1 diabetes and […]

Continue reading …
Page 1 of 212